玻璃体内贝伐珠单抗生物仿制药(MVASI)的安全性。

IF 4.9 2区 医学 Q1 OPHTHALMOLOGY
Hanru Wang, Bobak Bahrami, Sonia Huang, Marzieh Tahmasebi Sarvestani, Sudha Cugati, Stewart Lake, Weng Onn Chan, Devaraj Supramaniam, Matthew Little
{"title":"玻璃体内贝伐珠单抗生物仿制药(MVASI)的安全性。","authors":"Hanru Wang, Bobak Bahrami, Sonia Huang, Marzieh Tahmasebi Sarvestani, Sudha Cugati, Stewart Lake, Weng Onn Chan, Devaraj Supramaniam, Matthew Little","doi":"10.1111/ceo.14515","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Intravitreal bevacizumab has been used off-label to treat multiple ocular conditions for almost two decades. Reference bevacizumab, Avastin, was discontinued in Australia in 2021. A bevacizumab biosimilar, MVASI, was approved by the Therapeutic Goods Administration for the treatment of metastatic cancer in 2020. There is limited safety data for the off-label intravitreal use of MVASI. This retrospective study evaluates the safety of intravitreal MVASI.</p><p><strong>Methods: </strong>Retrospective review of all eyes that were given intravitreal MVASI at all metropolitan public hospitals in South Australia between 1st May 2022 and 30th May 2024. Demographic data, injection indications, number of injections per eye, whether patients were switched to another agent, and associated complications were collected from electronic and paper medical records.</p><p><strong>Results: </strong>A total of 6230 injections were given to 1682 eyes in this study. The mean age of the study population was 69.8 ± 15.6 years. The overall mean number of MVASI injections given per eye was 3.7 ± 2.9 (range 1-21). The indications for treatment were neovascular age-related macular degeneration (2106 injections; 33.8%), diabetic macular oedema (1634 injections; 26.2%), branch retinal vein occlusion (695 injections; 11.2%), proliferative diabetic retinopathy (596 injections; 9.6%), central retinal vein occlusion (558 injections; 9.0%) and other (641 injections; 10.3%). Significant sight-threatening complications included 3 cases of bacterial endophthalmitis (0.05%) and 3 cases of uveitis (0.05%). No cases of retinal vasculitis were observed.</p><p><strong>Conclusions: </strong>Intravitreal MVASI had a similar ophthalmic safety profile and may be used as an alternative to Avastin.</p>","PeriodicalId":55253,"journal":{"name":"Clinical and Experimental Ophthalmology","volume":" ","pages":""},"PeriodicalIF":4.9000,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Safety of an Intravitreal Bevacizumab Biosimilar (MVASI).\",\"authors\":\"Hanru Wang, Bobak Bahrami, Sonia Huang, Marzieh Tahmasebi Sarvestani, Sudha Cugati, Stewart Lake, Weng Onn Chan, Devaraj Supramaniam, Matthew Little\",\"doi\":\"10.1111/ceo.14515\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Intravitreal bevacizumab has been used off-label to treat multiple ocular conditions for almost two decades. Reference bevacizumab, Avastin, was discontinued in Australia in 2021. A bevacizumab biosimilar, MVASI, was approved by the Therapeutic Goods Administration for the treatment of metastatic cancer in 2020. There is limited safety data for the off-label intravitreal use of MVASI. This retrospective study evaluates the safety of intravitreal MVASI.</p><p><strong>Methods: </strong>Retrospective review of all eyes that were given intravitreal MVASI at all metropolitan public hospitals in South Australia between 1st May 2022 and 30th May 2024. Demographic data, injection indications, number of injections per eye, whether patients were switched to another agent, and associated complications were collected from electronic and paper medical records.</p><p><strong>Results: </strong>A total of 6230 injections were given to 1682 eyes in this study. The mean age of the study population was 69.8 ± 15.6 years. The overall mean number of MVASI injections given per eye was 3.7 ± 2.9 (range 1-21). The indications for treatment were neovascular age-related macular degeneration (2106 injections; 33.8%), diabetic macular oedema (1634 injections; 26.2%), branch retinal vein occlusion (695 injections; 11.2%), proliferative diabetic retinopathy (596 injections; 9.6%), central retinal vein occlusion (558 injections; 9.0%) and other (641 injections; 10.3%). Significant sight-threatening complications included 3 cases of bacterial endophthalmitis (0.05%) and 3 cases of uveitis (0.05%). No cases of retinal vasculitis were observed.</p><p><strong>Conclusions: </strong>Intravitreal MVASI had a similar ophthalmic safety profile and may be used as an alternative to Avastin.</p>\",\"PeriodicalId\":55253,\"journal\":{\"name\":\"Clinical and Experimental Ophthalmology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":4.9000,\"publicationDate\":\"2025-03-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and Experimental Ophthalmology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/ceo.14515\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/ceo.14515","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

本文章由计算机程序翻译,如有差异,请以英文原文为准。
Safety of an Intravitreal Bevacizumab Biosimilar (MVASI).

Background: Intravitreal bevacizumab has been used off-label to treat multiple ocular conditions for almost two decades. Reference bevacizumab, Avastin, was discontinued in Australia in 2021. A bevacizumab biosimilar, MVASI, was approved by the Therapeutic Goods Administration for the treatment of metastatic cancer in 2020. There is limited safety data for the off-label intravitreal use of MVASI. This retrospective study evaluates the safety of intravitreal MVASI.

Methods: Retrospective review of all eyes that were given intravitreal MVASI at all metropolitan public hospitals in South Australia between 1st May 2022 and 30th May 2024. Demographic data, injection indications, number of injections per eye, whether patients were switched to another agent, and associated complications were collected from electronic and paper medical records.

Results: A total of 6230 injections were given to 1682 eyes in this study. The mean age of the study population was 69.8 ± 15.6 years. The overall mean number of MVASI injections given per eye was 3.7 ± 2.9 (range 1-21). The indications for treatment were neovascular age-related macular degeneration (2106 injections; 33.8%), diabetic macular oedema (1634 injections; 26.2%), branch retinal vein occlusion (695 injections; 11.2%), proliferative diabetic retinopathy (596 injections; 9.6%), central retinal vein occlusion (558 injections; 9.0%) and other (641 injections; 10.3%). Significant sight-threatening complications included 3 cases of bacterial endophthalmitis (0.05%) and 3 cases of uveitis (0.05%). No cases of retinal vasculitis were observed.

Conclusions: Intravitreal MVASI had a similar ophthalmic safety profile and may be used as an alternative to Avastin.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
7.60
自引率
12.50%
发文量
150
审稿时长
4-8 weeks
期刊介绍: Clinical & Experimental Ophthalmology is the official journal of The Royal Australian and New Zealand College of Ophthalmologists. The journal publishes peer-reviewed original research and reviews dealing with all aspects of clinical practice and research which are international in scope and application. CEO recognises the importance of collaborative research and welcomes papers that have a direct influence on ophthalmic practice but are not unique to ophthalmology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信